Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
3

Story being shared
Bigger, lengthier clinical trials could help in finding a cure for ALS
More than 20 experimental drugs have failed in clinical trials as treatments for amyotrophic lateral sclerosis. Biogen Idec's dexpramipexole was abandoned when it failed to help patients in a phase III trial. Steve Perrin, CEO of the ALS Therapy Development Institute, says that phase II trials should involve more patients for longer periods to determine how to proceed in phase III. "All of the drugs that have failed recently in Phase III looked promising at Phase II," he said. "The lesson here is that we need to change the design in Phase II."

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .